Clinical Trial Detail

NCT ID NCT03872427
Title Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, CB-839 HCl, Anti-Cancer Treatment, BeGIN Study
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

malignant peripheral nerve sheath tumor

Advanced Solid Tumor

Therapies

Telaglenastat

Age Groups: adult senior

Additional content available in CKB BOOST